What Is the E2B(R3) Deadline and Does It Affect Your Organisation?
If your organisation submits Individual Case Safety Reports to the FDA, whether for approved products or investigational new drugs, you are facing one of the most operationally significant pharmacovigilance deadlines in years. On 1 April 2026, the FDA will make E2B(R3) mandatory for all electronic ICSR submissions. Organisations currently submitting in the legacy E2B(R2) format have had a two-year transition period to implement the new standard, and that window closes on 1 April 2026.
This is not a technical upgrade that can be handled quietly in the background. It touches every part of your ICSR workflow, from intake and triage through data entry, quality control, narrative writing, and submission. And if you outsource any part of your safety reporting, it affects your vendors too.
This blog explains what E2B(R3) is, what has actually changed from R2, who is affected, what the two submission pathways look like in practice, and exactly what your pharmacovigilance team needs to do right now to be compliant on 1 April 2026.
What Is E2B(R3) and Why Is the FDA Moving to It Now?
E2B is the ICH international standard for the electronic transmission of Individual Case Safety Reports between pharmaceutical companies, sponsors, and regulatory authorities. The change from E2B(R2) to E2B(R3) was driven by the need to improve data quality, enhance standardisation, increase interoperability with other clinical systems, and better align with global reporting needs.
E2B(R3) is built on the HL7 Reference Information Model, providing an object-oriented structure for adverse event data and leveraging ISO Identification of Medicinal Products standards to enable rich, globally consistent ICSR data. In plain terms, this means a shift from the older SGML-based message format used in R2 to a structured XML-based format that is more granular, more interoperable, and better suited to modern pharmacovigilance signal detection.
Major regulatory authorities across multiple jurisdictions have confirmed adoption of E2B(R3) as their standard format for adverse event reporting. The European regulatory authority has been operating on E2B(R3) through its centralised adverse event database since 2017. The FDA’s mandatory deadline of 1 April 2026 is the final step in achieving true global harmonisation across the world’s largest pharmaceutical regulatory jurisdictions.
What Has Actually Changed: R2 Versus R3
Understanding the practical differences between E2B(R2) and E2B(R3) is essential before you can assess where your current submission process falls short. The changes are not cosmetic. They affect data structure, field architecture, and how information is captured and transmitted.
Key differences between E2B(R2) and E2B(R3):
- Format: R2 uses an SGML-based message format. R3 uses a structured XML format based on HL7 standards, which enables richer data and better interoperability with clinical systems
- Data architecture: In R3, certain data elements have moved from case level to event level, meaning more granular reporting of individual adverse events within a single case
- New data fields: R3 introduces new regional data elements, expanded code lists, and additional fields that do not exist in R2, including fields for literature references, study identifiers, and expanded product information
- Attachments: In R3, attachments such as literature articles can now be incorporated directly into the ICSR XML file, supporting standard document formats. This is not possible in R2
- Null flavours: R3 introduces the concept of null flavours, which allow reporters to specify the reason a mandatory field has not been populated, for example because the information was asked for but is unknown, or because it is masked for privacy reasons. This replaces the binary present or absent approach in R2
- Data privacy: R3 includes stronger built-in data privacy controls through the null flavour framework and structured masking fields
- Standardised terminology: R3 uses ISO-aligned controlled terminology and code sets throughout, replacing the less standardised free-text approach common in R2
Once a sponsor submits their first E2B(R3) report for a specific product, they are locked into that standard and cannot revert to legacy methods or R2 format for that product. This lock-in makes it essential that your system and processes are fully validated before you submit your first R3 case.
Who Is Affected by the April 2026 Deadline
The scope of the mandate is broader than some organisations have assumed. The following categories are directly affected:
- Holders of approved new drug applications, abbreviated new drug applications, or biologics licence applications currently submitting postmarketing ICSRs to the FDA’s adverse event reporting system in E2B(R2) format
- IND sponsors currently submitting premarketing safety reports using paper forms or other legacy formats
- Sponsors who previously submitted via narrative forms, for whom E2B(R3) now requires significant updates to ICSR submission processes
- Contract research organisations and pharmacovigilance service providers submitting ICSRs on behalf of sponsors
- Companies with combination products requiring routing to multiple FDA centres
Organisations not affected by the April 2026 deadline include those that are not currently submitting ICSRs electronically to the FDA in E2B(R2) format, for example those submitting via the FDA’s web-based portal for manual submissions, for whom no action is required.
Importantly, not all IND safety reports qualify for E2B(R3) submission. Reports detailing findings from other studies, animal or in vitro testing results, or observations of increased incidence rates still require electronic common technical document submission, as these reports require contextual narrative explanation and study interpretation that cannot be fully captured within standardised XML fields. Sponsors must therefore maintain two distinct submission pathways going forward.
The Two Submission Pathways Under E2B(R3)
Under the FDA’s implementation of E2B(R3), sponsors have two primary options for submitting ICSRs: automated electronic transmission via the FDA’s Electronic Submissions Gateway, or manual entry through the FDA’s web-based Safety Reporting Portal.
The Electronic Submissions Gateway pathway:
- Designed for organisations with high reporting volumes and established IT infrastructure
- Requires a registered and FDA-approved Batch Sender Identifier before any submission can be made
- Requires correct routing identifiers at both batch and message level: the Batch Receiver Identifier and the Message Receiver Identifier must specify the correct regulatory centre and report type
- Incorrect routing identifiers will result in outright submission rejection
- Provides automated acknowledgement receipts enabling full audit trail traceability
- Requires prior testing in the FDA’s pre-production validation environment before any live production submissions
The Safety Reporting Portal pathway:
- More accessible for smaller organisations or those with limited IT capability
- Requires manual data entry of each ICSR directly into a web-based form
- Still requires familiarity with the E2B(R3) data structure and adherence to the FDA’s technical conformance guidelines
- Does not require a separate gateway account or XML generation capability
- Less scalable for high-volume reporting
For organisations currently submitting through the web-based portal with no E2B involvement, no action is required to meet the April 2026 deadline. However, organisations anticipating growth in reporting volume should evaluate whether the gateway pathway is more appropriate for their operations going forward.
The Operational Impact on Your ICSR Processing Workflow
E2B(R3) compliance is not only a system upgrade. It changes how your PV team works at every stage of the ICSR lifecycle. The operational impact across each stage is as follows.
Intake and triage:
- Source documents must now be assessed against the expanded R3 data field requirements from the point of intake
- Triage procedures must flag cases requiring dual-pathway submission, distinguishing those that qualify for E2B(R3) XML from those that require electronic common technical document submission
- Case ownership and routing responsibilities must be documented clearly, particularly for organisations with both IND and postmarketing portfolios
Data entry and case processing:
- All mandatory and conditionally mandatory fields in the R3 XML structure must be populated at case level and event level
- Null flavours must be applied correctly where information is unavailable, rather than leaving fields blank
- Product information must align with global substance registration naming conventions where applicable
- Combination product cases require additional routing logic based on primary mode of action
Quality control:
- QC procedures must include XML schema validation before submission to catch structural errors that would cause rejection
- Business rule validation must be conducted against FDA-specific regional requirements, which extend beyond the base ICH E2B(R3) standard
- Common validation failures include missing mandatory fields, misaligned patient data, and incompatible file encodings, all of which must be caught during internal QC before submission
Narrative writing:
- Case narratives remain a required component of the R3 ICSR and must be structured to support the expanded data richness of the new format
- Literature attachments can now be embedded directly in the XML file, which changes how literature-sourced cases are documented and submitted
Submission and tracking:
- Acknowledgement management must be built into your workflow, and any rejections must trigger an investigation and resubmission process
- Submission timelines of 15 days for serious cases remain unchanged and must be maintained throughout the transition
What Your Organisation Must Do Before 1 April 2026
The following actions are required for any organisation that has not yet completed E2B(R3) implementation:
- Confirm your submission pathway: determine whether you will use the gateway or web portal route and initiate any necessary account registration or system configuration immediately
- Register your Batch Sender Identifier with the FDA if using the gateway pathway, as this requires prior approval and cannot be done on the day of first submission
- Upgrade or validate your safety database: confirm that your pharmacovigilance system generates compliant E2B(R3) XML and has been tested in the FDA’s pre-production environment
- Update all ICSR SOPs: revise procedures for intake, triage, data entry, QC, narrative writing, and submission to reflect R3 requirements, dual-pathway logic, and null flavour application
- Conduct staff training: ensure all PV team members, including outsourced service providers, understand the R3 data structure, mandatory field requirements, and the FDA’s regional technical specifications
- Audit your CRO or PV vendor: if you outsource ICSR processing or submission, confirm that your service provider is E2B(R3) compliant and has successfully tested in the FDA’s pre-production environment
- Map your IND safety report portfolio: identify all cases that will require electronic common technical document submission rather than E2B(R3) and confirm your dual-pathway SOPs are in place
- Run parallel testing: submit test cases in R3 format through the FDA’s staging environment and resolve any validation errors before your first live production submission
How Quality and Vigilance Ltd Can Help
At Quality and Vigilance Ltd, we provide specialist pharmacovigilance technical services to help organisations achieve and maintain ICSR submission compliance across global regulatory authorities. Our services directly relevant to E2B(R3) readiness include:
- ICSR processing support covering intake, triage, data entry, quality control, narrative writing, and regulatory authority submission in both E2B and non-E2B formats
- E2B(R3) and non-E2B submission support for FDA, EMA, and worldwide regulatory authorities
- Pharmacovigilance system audits to assess your current ICSR workflow, identify E2B(R3) compliance gaps, and provide a remediation roadmap
- SOP development and controlled document review for ICSR processing, QC, and submission procedures updated for R3 requirements
- Vendor and CRO audit services to verify that your outsourced ICSR partners are compliant with the April 2026 mandate
- Training on E2B(R3) requirements, FDA regional technical specifications, and dual-pathway submission logic for PV teams and regulatory operations staff
- PV system setup and ongoing compliance monitoring for organisations building or restructuring their ICSR submission infrastructure
Get in touch with our team to discuss your current ICSR submission process, where your E2B(R3) gaps are, and what steps you need to take before the 1 April 2026 deadline.